Laser microdissection and two-dimensional difference gel electrophoresis reveal proteomic intra-tumor heterogeneity in colorectal cancer

Journal of Proteomics

Volumn 78, Issue , 2013, Pages 134-147

  Sugihara, Yutaka ^a   Taniguchi, Hirokazu ^b   Kushima, Ryoji ^b   Tsuda, Hitoshi ^b   Kubota, Daisuke ^a   Ichikawa, Hiroshi ^a   Fujita, Shin ^b   Kondo, Tadashi ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Colorectal cancer; Intra tumor heterogeneity; Laser microdissection; Two dimensional difference gel electrophoresis

Indexed keywords

ADULT; AGED; ARTICLE; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; HUMAN TISSUE; LASER MICRODISSECTION; MALE; MASS SPECTROMETRY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; STRESS; TISSUE DISTRIBUTION; TUMOR CELL; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS;

ADULT; AGED; COLORECTAL NEOPLASMS; EPITHELIAL CELLS; FEMALE; HUMANS; LASER CAPTURE MICRODISSECTION; MALE; MASS SPECTROMETRY; MIDDLE AGED; NEOPLASM PROTEINS; PROTEOMICS; TWO-DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS;

EID: 84871778930     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2012.11.009     Document Type: Article

References (42)

1. Marusyk A., Almendro V., Polyak K. Intra-tumour heterogeneity: a looking glass for cancer?. Nat Rev Cancer 2012, 12:323-334.
2. De Wever O., Mareel M. Role of tissue stroma in cancer cell invasion. J Pathol 2003, 200:429-447.
3. Brabletz T., Jung A., Reu S., Porzner M., Hlubek F., Kunz-Schughart L.A., et al. Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci U S A 2001, 98:10,356-10,361.
4. Spaderna S., Schmalhofer O., Hlubek F., Berx G., Eger A., Merkel S., et al. A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer. Gastroenterology 2006, 131:830-840.
5. Helczynska K., Kronblad A., Jogi A., Nilsson E., Beckman S., Landberg G., et al. Hypoxia promotes a dedifferentiated phenotype in ductal breast carcinoma in situ. Cancer Res 2003, 63:1441-1444.
6. Kahlert C., Klupp F., Brand K., Lasitschka F., Diederichs S., Kirchberg J., et al. Invasion front-specific expression and prognostic significance of microRNA in colorectal liver metastases. Cancer Sci 2011, 102:1799-1807.
7. Kahlert C., Lahes S., Radhakrishnan P., Dutta S., Mogler C., Herpel E., et al. Overexpression of ZEB2 at the invasion front of colorectal cancer is an independent prognostic marker and regulates tumor invasion in vitro. Clin Cancer Res 2011, 17:7654-7663.
8. Thorn C.C., Freeman T.C., Scott N., Guillou P.J., Jayne D.G. Laser microdissection expression profiling of marginal edges of colorectal tumours reveals evidence of increased lactate metabolism in the aggressive phenotype. Gut 2009, 58:404-412.
9. Raza S.M., Fuller G.N., Rhee C.H., Huang S., Hess K., Zhang W., et al. Identification of necrosis-associated genes in glioblastoma by cDNA microarray analysis. Clin Cancer Res 2004, 10:212-221.
10. Yoshino S., Hara T., Weng J.S., Takahashi Y., Seiki M., Sakamoto T. Genetic screening of new genes responsible for cellular adaptation to hypoxia using a genome-wide shRNA library. PLoS One 2012, 7:e35590.
11. Weitz J., Koch M., Debus J., Hohler T., Galle P.R., Buchler M.W. Colorectal cancer. Lancet 2005, 365:153-165.
12. Pfister D.G., Benson A.B., Somerfield M.R. Clinical practice. Surveillance strategies after curative treatment of colorectal cancer. N Engl J Med 2004, 350:2375-2382.
13. Liefers G.J., Tollenaar R.A. Cancer genetics and their application to individualised medicine. Eur J Cancer 2002, 38:872-879.
14. Popa-Velea O., Cernat B., Tambu A. Influence of personalized therapeutic approach on quality of life and psychiatric comorbidity in patients with advanced colonic cancer requiring palliative care. J Med Life 2010, 3:343-347.
15. Walther A., Johnstone E., Swanton C., Midgley R., Tomlinson I., Kerr D. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 2009, 9:489-499.
16. Goranova T.E., Ohue M., Shimoharu Y., Kato K. Dynamics of cancer cell subpopulations in primary and metastatic colorectal tumors. Clin Exp Metastasis 2011, 28:427-435.
17. Kahlert C., Bandapalli O.R., Schirmacher P., Weitz J., Brand K. Invasion front-specific overexpression of tissue inhibitor of metalloproteinase-1 in liver metastases from colorectal cancer. Anticancer Res 2008, 28:1459-1465.
18. Barderas R., Babel I., Casal J.I. Colorectal cancer proteomics, molecular characterization and biomarker discovery. Proteomics Clin Appl 2010, 4:159-178.
19. Bitarte N., Bandres E., Zarate R., Ramirez N., Garcia-Foncillas J. Moving forward in colorectal cancer research, what proteomics has to tell. World J Gastroenterol 2007, 13:5813-5821.
20. Nibbe R.K., Koyuturk M., Chance M.R. An integrative-omics approach to identify functional sub-networks in human colorectal cancer. PLoS Comput Biol 2010, 6:e1000639.
21. Alfonso P., Canamero M., Fernandez-Carbonie F., Nunez A., Casal J.I. Proteome analysis of membrane fractions in colorectal carcinomas by using 2D-DIGE saturation labeling. J Proteome Res 2008, 7:4247-4255.
22. Ma Y., Zhao M., Zhong J., Shi L., Luo Q., Liu J., et al. Proteomic profiling of proteins associated with lymph node metastasis in colorectal cancer. J Cell Biochem 2010, 110:1512-1519.
23. Ang C.S., Nice E.C. Targeted in-gel MRM: a hypothesis driven approach for colorectal cancer biomarker discovery in human feces. J Proteome Res 2010, 9:4346-4355.
24. Chen J.S., Chen K.T., Fan C.W., Han C.L., Chen Y.J., Yu J.S., et al. Comparison of membrane fraction proteomic profiles of normal and cancerous human colorectal tissues with gel-assisted digestion and iTRAQ labeling mass spectrometry. FEBS J 2010, 277:3028-3038.
25. Xie L.Q., Zhao C., Cai S.J., Xu Y., Huang L.Y., Bian J.S., et al. Novel proteomic strategy reveal combined alpha1 antitrypsin and cathepsin D as biomarkers for colorectal cancer early screening. J Proteome Res 2010, 9:4701-4709.
26. Pedersen J.W., Blixt O., Bennett E.P., Tarp M.A., Dar I., Mandel U., et al. Seromic profiling of colorectal cancer patients with novel glycopeptide microarray. Int J Cancer 2011, 128:1860-1871.
27. Spisak S., Galamb B., Sipos F., Galamb O., Wichmann B., Solymosi N., et al. Applicability of antibody and mRNA expression microarrays for identifying diagnostic and progression markers of early and late stage colorectal cancer. Dis Markers 2010, 28:1-14.
28. Morishita A., Gong J., Nomura T., Yoshida H., Izuishi K., Suzuki Y., et al. The use of protein array to identify targetable receptor tyrosine kinases for treatment of human colon cancer. Int J Oncol 2010, 37:829-835.
29. Sobin L., Gospodarowicz M., Wittekind C. 7th TNM classification of malignant tumours 2009, Wiley-Blackwell. 7th ed.
30. Kondo T., Hirohashi S. Application of highly sensitive fluorescent dyes (CyDye DIGE Fluor saturation dyes) to laser microdissection and two-dimensional difference gel electrophoresis (2D-DIGE) for cancer proteomics. Nat Protoc 2007, 1:2940-2956.
31. Kondo T., Seike M., Mori Y., Fujii K., Yamada T., Hirohashi S. Application of sensitive fluorescent dyes in linkage of laser microdissection and two-dimensional gel electrophoresis as a cancer proteomic study tool. Proteomics 2003, 3:1758-1766.
32. Hatakeyama H., Kondo T., Fujii K., Nakanishi Y., Kato H., Fukuda S., et al. Protein clusters associated with carcinogenesis, histological differentiation and nodal metastasis in esophageal cancer. Proteomics 2006, 6:6300-6316.
33. Bellot G.L., Tan W.H., Tay L.L., Koh D., Wang X. Reliability of tumor primary cultures as a model for drug response prediction: expression profiles comparison of tissues versus primary cultures from colorectal cancer patients. J Cancer Res Clin Oncol 2012, 138:463-482.
34. Fruehauf J.P., Alberts D.S. In vitro drug resistance versus chemosensitivity: two sides of different coins. J Clin Oncol 2005, 23:3641-3643. [author reply 6-8].
35. Uemura N., Nakanishi Y., Kato H., Saito S., Nagino M., Hirohashi S., et al. Transglutaminase 3 as a prognostic biomarker in esophageal cancer revealed by proteomics. Int J Cancer 2009, 124:2106-2115.
36. Yamada M., Fujii K., Koyama K., Hirohashi S., Kondo T. The proteomic profile of pancreatic cancer cell lines corresponding to carcinogenesis and metastasis. J. Proteomics Bioinform 2009, 02:1-18.
37. Orimo T., Ojima H., Hiraoka N., Saito S., Kosuge T., Kakisaka T., et al. Proteomic profiling reveals the prognostic value of adenomatous polyposis coli-end-binding protein 1 in hepatocellular carcinoma. Hepatology 2008, 48:1851-1863.
38. Muto T., Taniguchi H., Kushima R., Tsuda H., Yonemori H., Chen C., et al. Global expression study in colorectal cancer on proteins with alkaline isoelectric point by two-dimensional difference gel electrophoresis. J Proteomics 2011, 74:858-873.
39. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314.
40. Kato K., Kawashiri S., Yoshizawa K., Kitahara H., Yamamoto E. Apoptosis-associated markers and clinical outcome in human oral squamous cell carcinomas. J Oral Pathol Med 2008, 37:364-371.
41. Yamauchi M., Morikawa T., Kuchiba A., Imamura Y., Qian Z.R., Nishihara R., et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut 2012, 61:847-854.
42. Yamauchi M., Lochhead P., Morikawa T., Huttenhower C., Chan A.T., Giovannucci E., et al. Colorectal cancer: a tale of two sides or a continuum?. Gut 2012, 61:794-797.